NEUROTEC PHARMA
Neurotec Pharma SL is a spin-off of the University of Barcelona (UB) founded in 2006 and based in the Parc CientÃÂfic de Barcelona (PCB). Neurotec centers its activity on developing new treatments for acute and chronic Central Nervous System (CNS) diseases. The proposed innovations are based in the possibility of controlling the activity of the microglia cells that are implicated in a wide group of diseases related to inflammation or acute cerebral damage.
NEUROTEC PHARMA
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2006-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.neurotec-pharma.com
Total Employee:
11+
Status:
Active
Contact:
34 93 402 45 25
Email Addresses:
[email protected]
Total Funding:
3.3 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apache Euro
Similar Organizations
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Nordic Rebalance
Nordic Rebalance primarily focussed on developing a dietary treatment for irritable bowel syndrome and inflammatory bowel diseases.
Current Employees Featured
Founder
Investors List
Fundación Caja Navarra
Fundación Caja Navarra investment in Venture Round - Neurotec Pharma
Inveready
Inveready investment in Venture Round - Neurotec Pharma
Official Site Inspections
http://www.neurotec-pharma.com
- Host name: eu291a.odoo.com
- IP address: 145.239.155.21
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Neurotec Pharma"
Neurotec Pharma - Crunchbase Company Profile & Funding
Neurotec Pharma is focused on developing new treatments for acute and chronic central nervous system (CNS) diseases. Neurotec Pharma SL is a spin-off of the University of Barcelona (UB) …See details»
Neurotech Pharmaceuticals, Inc. - Encapsulated Cell Therapy
Jun 20, 2024 · Neurotech Pharmaceuticals, Inc. Neurotech is a private clinical stage biotech company focused on developing transformative therapies for chronic eye disease. The core …See details»
Neurotec Pharma - Contacts, Employees, Board Members
Neurotec Pharma has 4 current employee profiles, including Founder and Chief Executive Officer Marco Pugliese. Neurotec Pharma is focused on developing new treatments for acute and …See details»
Neurotec Pharma Company Profile - Office Locations, Competitors …
Neurotec Pharma is a company that develops diagnostic and therapeutic tools for acute and chronic central nervous system (CNS) diseases. Its technologies aim to control the activity of …See details»
Neurotec Pharma, S.L. - VentureRadar
Website: http://www.neurotec-pharma.com/ Develops innovative therapies for acute and chronic central nervous system diseases, aiming to improve patient outcomes and quality of life. …See details»
Neurotec Pharma - Overview, News & Competitors | ZoomInfo.com
View Neurotec Pharma (www.neurotec-pharma.com) location in Catalonia, Spain , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Neurotec Pharma - Funding, Financials, Valuation & Investors
Neurotec Pharma is focused on developing new treatments for acute and chronic central nervous system (CNS) diseases.See details»
News | Press Releases | Neurotech Pharmaceuticals, Inc
Nov 2, 2022 · Learn more and get updates on Neurotech Pharmaceuticals corporate and how we deliver MacTel treatment solutions.See details»
Macular Telangiectasia | About Neurotech …
At Neurotech, we are focused on developing transformative therapies for chronic retinal diseases. Our unique scientific approach and novel Encapsulated Cell Therapy Platform promotes therapeutic advancements to treat a broad array …See details»
Start of in-patient clinical trials with NT-KO-003, the …
The biotechnological companies Advancell and Neurotec Pharma, both based in Barcelona Science Park (PCB), Spain, have announced the initiation of a clinical Phase IIa study with NT-KO-003, an innovative oral therapy for multiple …See details»
Luiz Calistro Balestrassi – Founder and President - Neurotec
Prof. Dr. Luiz Calistro Balestrassi, founder and president of NEUROTEC - Biomedical Research & Development Company from Itajubá-MG, Brazil, and his daughter Esperança Balestrassi, …See details»
Marco Pugliese - Founder and Chief Executive Officer @ Neurotec …
Marco Pugliese has 2 current jobs as Founder and Chief Executive Officer at Neurotec Pharma and Co-Founder at 20lines.See details»
NT-KC-005 - Drug Targets, Indications, Patents - Synapse - Patsnap
NT-KC-005, Initially developed by Neurotec Pharma SL, Now, its global highest R&D status is Pending, Therapeutic Areas: Nervous System Diseases,Cardiovascular Diseases.See details»
Start of in-Patient Clinical Trials With NT-KO-003, the First ...
Jul 19, 2011 · The biotechnological companies Advancell and Neurotec Pharma, both based in Barcelona Science Park (PCB), Spain, have announced the initiation of a clinical Phase IIa …See details»
Encapsulated Cell Therapy | Science & Technology | Neurotech
To circumvent the relatively short half-lives of therapeutic protein drugs and provide a steady-state therapeutic and safe concentration following single intraocular application, a novel cell-therapy …See details»
Advancell Release: Start of in-Patient Clinical Trials With ... - BioSpace
Jul 19, 2011 · The biotechnological companies Advancell and Neurotec Pharma, both based in Barcelona Science Park (PCB), Spain, have announced the initiation of a clinical Phase IIa …See details»
is Now Available in Canada for the Treatment of Acute Migraine
KIRKLAND, QC, April 4, 2024 –NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age. …See details»
Neurotec Pharma - Tech Stack, Apps, Patents & Trademarks
Neurotec Pharma is focused on developing new treatments for acute and chronic central nervous system (CNS) diseases.See details»
FDA Approves First Drug for Both Migraine Treatment and …
May 28, 2021 · Nurtec is a calcitonin gene-related peptide (CGRP) inhibitor, a relatively new class of medication that blocks a protein released during migraine attacks from binding to nerve …See details»
FDA Approves First Drug for Migraine Treatment and Prevention
Jun 14, 2021 · Now, the Food and Drug Administration (FDA) has approved the first drug that can do both. The FDA initially approved rimegepant (Nurtec ODT) for acute use—to treat an …See details»